Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Arthritis Associates of South Florida
mi
from
Delray Beach, FL
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Arthritis Associates of South Florida
mi
from
Delray Beach, FL
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Delray Research Associates
mi
from
Delray Beach, FL
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Delray Research Associates
mi
from
Delray Beach, FL
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Miami Children's Hospital
mi
from
Miami, FL
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Administrative Site-Hawaii Pacific Health Research Institute
mi
from
Honolulu, HI
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Administrative Site-Hawaii Pacific Health Research Institute
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Kosair Charities Pediatric Clinical Research Unit / University of Louisville
mi
from
Louisville, KY
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Kosair Charities Pediatric Clinical Research Unit / University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Kosair Children's Hospital
mi
from
Louisville, KY
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
University of Louisville
mi
from
Louisville, KY
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
University Pediatric Rheumatology of Kentucky, LLC
mi
from
Louisville, KY
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
University Pediatric Rheumatology of Kentucky, LLC
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Childrens Hospital & Medical Center
mi
from
Omaha, NE
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Childrens Hospital & Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
University of Nebraska Medical Center Pediatric Research Office
mi
from
Omaha, NE
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
University of Nebraska Medical Center Pediatric Research Office
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Akron Children's Hospital
mi
from
Akron, OH
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Akron Children's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated:  10/7/2015
Hospital Roberto del Rio
mi
from
Santiago,
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.
Status: Enrolling
Updated: 10/7/2015
Hospital Roberto del Rio
mi
from
Santiago,
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Mesa, AZ
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Peoria, AZ
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Peoria, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Little Rock, AR
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Santa Monica, CA
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Coeur d'Alene, ID
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigational Site
mi
from
Springfield, IL
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Kalamazoo, MI
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Lincoln, NE
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Rochester, NY
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Tulsa, OK
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Greenville, SC
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Jackson, TN
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Jackson, TN
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated:  10/7/2015
Novartis Investigative Site
mi
from
Bruxelles,
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
Status: Enrolling
Updated: 10/7/2015
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.
Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.
Status: Enrolling
Updated:  10/11/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.
Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.
Status: Enrolling
Updated: 10/11/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
Johns Hopkins University
mi
from
Baltimore, MD
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
Stanford University
mi
from
Palo Alto, CA
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
University of Colorado Denver
mi
from
Aurora, CO
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
North Shore Medical Center (LIJ Health System)
mi
from
Lake Success, NY
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
North Shore Medical Center (LIJ Health System)
mi
from
Lake Success, NY
Click here to add this to my saved trials
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated:  10/12/2015
Duke University
mi
from
Durham, NC
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
Status: Enrolling
Updated: 10/12/2015
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Ultrasound Guided vs Unguided Intra-articular Knee Injections
Accuracy of Ultrasound Guided Versus Unguided Intra-articular Knee Injections in a Difficult to Inject Population
Status: Enrolling
Updated:  10/13/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Ultrasound Guided vs Unguided Intra-articular Knee Injections
Accuracy of Ultrasound Guided Versus Unguided Intra-articular Knee Injections in a Difficult to Inject Population
Status: Enrolling
Updated: 10/13/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel) Compared With Naproxen in Subjects With Osteoarthritis of the Knee. A Pilot Study
Status: Enrolling
Updated:  10/19/2015
Timothy Truitt MD
mi
from
Melbourne, FL
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel) Compared With Naproxen in Subjects With Osteoarthritis of the Knee. A Pilot Study
Status: Enrolling
Updated: 10/19/2015
Timothy Truitt MD
mi
from
Melbourne, FL
Click here to add this to my saved trials
Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee
A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi Center Study of Flavocoxid ( Limbrel) vs Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  10/19/2015
Primus Pharmaceuticals, Inc
mi
from
Scottsdale, AZ
Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee
A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi Center Study of Flavocoxid ( Limbrel) vs Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 10/19/2015
Primus Pharmaceuticals, Inc
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
Status: Enrolling
Updated:  10/20/2015
Rothman Institute
mi
from
Philadelphia, PA
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
Status: Enrolling
Updated: 10/20/2015
Rothman Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
Status: Enrolling
Updated:  10/20/2015
Anderson Orthopaedic Clinic
mi
from
Alexandria, VA
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach
Status: Enrolling
Updated: 10/20/2015
Anderson Orthopaedic Clinic
mi
from
Alexandria, VA
Click here to add this to my saved trials
Shoe Modification and Knee Osteoarthritis
Shoe Modification and Knee Osteoarthritis
Status: Enrolling
Updated:  10/20/2015
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Shoe Modification and Knee Osteoarthritis
Shoe Modification and Knee Osteoarthritis
Status: Enrolling
Updated: 10/20/2015
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated:  10/23/2015
Vertex Investigational Site
mi
from
Birmingham, AL
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated: 10/23/2015
Vertex Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated:  10/23/2015
Vertex Investigational Site
mi
from
Tustin, CA
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated: 10/23/2015
Vertex Investigational Site
mi
from
Tustin, CA
Click here to add this to my saved trials
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated:  10/23/2015
Vertex Investigational Site
mi
from
Boca Raton, FL
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated: 10/23/2015
Vertex Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated:  10/23/2015
Vertex Investigational Site
mi
from
Springfield, IL
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated: 10/23/2015
Vertex Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated:  10/23/2015
Vertex Investigational Site
mi
from
Wichita, KA
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated: 10/23/2015
Vertex Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated:  10/23/2015
Vertex Investigational Site
mi
from
Omaha, NE
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
Status: Enrolling
Updated: 10/23/2015
Vertex Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials